AFT Pharmaceuticals breached the consumer laws with misleading ads over the strength of its painkiller Maxigesic, a judge has found, siding with rival drug maker Reckitt Benckiser.
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
US tyre company Goodyear has dropped its challenge to a mixed trade mark ruling in its long-running dispute with UK-based rival Dunlop over coveted trade marks for ‘Dunlop’ and ‘Flying D’.
A unit of Fortescue Metals Group has won its bid for emails between Squire Patton Boggs and a unit of electricity provider TransAlta Energy relating to a disputed power purchase agreement, saying privilege was waived when the emails were forwarded to a third party.
A Federal Court judge has expressed her disbelief at a cross claim by generic drug maker Sandoz against Danish multinational H Lundbeck, as the court begins to weigh arguments over damages owed to Lundbeck in the long-running patent case over its blockbuster anti-depressant Lexapro.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world’s best-selling vaccine.
A judge has shot down a last minute bid by an insurance brokerage facing a cross claim in a class action over failed debenture issuer Provident Capital to retract an admission in its defence ahead of trial next month.
The judge presiding over two shareholder class actions against Murray Goulburn indicated Friday he would likely let both cases proceed jointly to a trial in 2020.
Liquidators for failed engineering services company Hastie Group have a fight on their hands over tens of millions of dollars in unpaid invoices from construction companies, with major builders claiming not only that they don’t have to pay, but that the bills aren’t payable.
The defendants in a shareholder class action over QRxPharma’s alleged failure to disclose problems with regulatory approval for its painkiller Moxduo have won access to information on class members’ financial brokers.